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Abstract: Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is
associated with a relatively high incidence of severe diarrhea. The association between pre-treatment
candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures
of body mass) and severe (grade ≥ 3) diarrhea was evaluated using logistic regression with pooled
individual participant data from seven clinical studies. A risk score was developed based on the
count of major risk factors. Overall, 184 of 1151 participants (16%) experienced severe diarrhea with
use of afatinib. Body weight, body mass index, and body surface area all exhibited a prominent
non-linear association where risk increased markedly at the lower range (p < 0.005). Low weight
(<45 kg), female sex, and older age (≥60 years) were identified as major independent risk factors
(p < 0.01). Each risk factor was associated with a two-fold increase in the odds of severe diarrhea, and
this was consistent between individuals commenced on 40 mg or 50 mg afatinib. A simple risk score
based on the count of these risk factors identifies individuals at lowest and highest risk (C-statistic
of 0.65). Risk of severe diarrhea for individuals commenced on 40 mg afatinib ranged from 6% for
individuals with no risk factors to 33% for individuals with all three risk factors.
Keywords: EGFR inhibitor; diarrhea; toxicity; prediction model; adverse event
1. Introduction
Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are an effective
treatment option for patients with non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR
mutation [1]. Use of afatinib, a second-generation EGFR inhibitor with favorable efficacy [2], has been
tempered by toxicity concerns. Diarrhea is the most common severe adverse event associated with the
use of afatinib and is observed at higher frequency compared to other EGFR inhibitors [3,4].
A series of relatively small studies have reported that the risk of diarrhea with afatinib may be
associated with low body surface area (BSA) [5], low body mass index (BMI) [6], low hemoglobin [6],
and female sex [7]. Furthermore, product information for afatinib (Giotrif®) highlights that female
sex, low body weight, and renal impairment are associated with higher afatinib exposure (i.e., drug
plasma concentration), and this may impact on the risk of toxicity [8,9]. This study aimed to evaluate
putative pre-treatment predictors of severe diarrhea in a larger patient population by pooling data
from clinical trials of afatinib for NSCLC, and to develop a simple tool that may be used in clinical
practice to estimate an individual’s risk of severe diarrhea with afatinib.
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2. Results
The pooled analysis set included 1151 participants using afatinib, of which 184 (16%) experienced
severe diarrhea. Incidence of severe diarrhea differed between studies, ranging between 6% to 37%.
The median time to grade 3–4 diarrhea was 18 days for individuals commenced on 40 mg afatinib
and 16 days for individuals commenced on 50 mg afatinib. Overall and study-specific participant
characteristics are summarized in Table 1 and Table S1, respectively.
Table 1. Summary of pre-treatment characteristics for study participants commencing afatinib.
Characteristic TotalNo. 1151












Prior EGFR inhibitor 479 (42%)
Prior chemotherapy 595 (52%)
Afatinib starting dose
40 mg 498 (43%)
50 mg 653 (57%)
Weight (kg)
Median (IQR) 61 (53–70)
Missing 3 (<1%)
Body mass index (kg/m2)
Median (IQR) 23 (21–26)
Missing 10 (1%)
Body surface area (m2)
Median (IQR) 1.7 (1.5–1.8)
Missing 10 (1%)
eGFR (mL/min/1.73 m2)
Median (IQR) 91 (76–109)
Missing 5 (<1%)
Hemoglobin (g/L)
Median (IQR) 128 (117–138)
Missing 5 (<1%)
ECOG PS: Eastern Cooperative Oncology Group performance status; eGFR: Estimated glomerular filtration rate;
IQR: interquartile range.
A non-linear association was identified for body weight, BSA, and BMI with an increased risk
of severe diarrhea primarily at the lower range (Figure 1). This association was present for both
individuals commenced on 40 mg or 50 mg afatinib. Very few males were in the weight/BSA range
for which risk was substantially increased (e.g., 3% of males vs. 22% of females had weight < 50 kg).
To aid interpretation and reporting, continuous variables were categorized into four groups based on
the visual inspection of the loess curves and established cut points. For weight, BSA, BMI, and eGFR
categories were selected to evaluate risk at progressively lower values. For age and hemoglobin, no
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significant non-linearity was apparent. Consequently, hemoglobin was categorized into quartiles, and
age was categorized into four similarly sized groups with cut-points falling at decades of age.
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Figure 1. Loess locally weighted smoothed relationship between risk of grade ≥3 diarrhea and (a) 
body weight, (b) body surface area, and (c) body mass index. 
Univariate analysis identified older age, female sex, low body weight, low BSA, and low BMI 
was most strongly associated with an increased risk of severe diarrhea (p < 0.005, Table 2). Lower 
eGFR, non-Asian race, and lower hemoglobin had a trend toward increased risk of severe diarrhea 
(p < 0.1, Table 2). No significant heterogeneity in variable effect size was apparent between studies or 
between different starting doses (40 mg or 50 mg) of afatinib (p > 0.05). Low weight, low BSA, and 
low BMI were highly correlated and, as they provided similar predictive performance, for simplicity 
weight was selected for inclusion in the multivariable analysis. 
Table 2. Logistic regression analysis * of association between pre-treatment characteristics and grade 
≥3 diarrhea with afatinib. 
Baseline Characteristics 
Univariate Analysis * Multivariable Analysis * 
Events/N (%) OR 95% CI p OR 95% CI p 
Sex    <0.001   <0.001 
Male 44/443 (10%) 1.00   1.00   
Female 140/708 (20%) 2.22 1.53–3.21  2.04 1.36–3.07  
Age (years)    <0.001   0.008 
27–49 21/237 (9%) 1.00   1.00   
50–59 40/319 (13%) 1.44 0.82–2.53  1.38 0.78–2.47  
60–69 78/373 (21%) 2.57 1.52–4.33  2.32 1.35–4.00  
70–86 45/222 (20%) 2.24 1.27–3.96  1.97 1.08–3.61  
Race †    0.080   0.079 
Asian 121/839 (14%) 1.00   1.00   
Non-Asian 63/312 (20%) 1.45 0.96–2.20  1.49 0.96–2.32  
Weight (kg)    <0.001   0.003 
≥50 138/977 (14%) 1.00   1.00   
45–49 22/102 (22%) 1.60 0.94–2.71  1.51 0.85–2.65  
40–44 16/56 (29%) 2.11 1.12–3.99  1.98 1.00–3.93  
<40 8/13 (62%) 8.81 2.72–28.5  7.93 2.32–27.1  
BMI (kg/m2)    0.002    
1. Loes locally weighted smoothed relationship between risk of grade ≥3 diarrhea and ( ) body
weight, (b) body surface area, and (c) body mass index.
Univariate analysis identified older age, female sex, low body weight, low BSA, and low BMI was
most strongly associated with an increased risk of severe diarrhea (p < 0.005, Table 2). Lower eGFR,
non-Asian race, and lower hemoglobin had a trend toward increased risk of severe diarrhea (p < 0.1,
Table 2). No significant heterogeneity in variable effect size was apparent between studies or between
different starting doses (40 mg or 50 g) of afatinib (p > 0.05). Low weight, low BSA, and low BMI
were highly correlated and, as they provided similar predictive performance, for simplicity weight
as selected for inclusion in the multivariable analysis.
Multivariable logistic regression analysis identified that older age, female sex, and low body
weight w re all significant independent predi tors of sev re diar hea (p < 0.01, Table 2). A sensitivity
analysis including adjustment for afatinib starting dose identified the same predictors (Table S2).
A simplified risk score was subsequently constructed including these three major factors. For
simplicity, age and weight were dichotomized using a single cut point identified from the results of
the multivariable analysis. For age, a cut point of 60 years was selected on the basis that the effect size
for the 60 to 69 years and ≥70 years age groups were similar and were substantially higher than that
of the 50 to 59 years age group. A cut point of <45 kg body weight was selected on the basis that this
would have an effect size similar to that of age and sex. As each risk factor had a similar independent
effect size (approximately doubling the odds), which was consistent for both 40 mg and 50 mg starting
afatinib doses, they were given equal weighting and the risk score was calculated as the simple count
of the major risk factors (female sex, age ≥60 years, and body weight <45 kg).
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Table 2. Logistic regression analysis * of association between pre-treatment characteristics and grade
≥3 diarrhea with afatinib.
Baseline Characteristics
Univariate Analysis * Multivariable Analysis *
Events/N (%) OR 95% CI p OR 95% CI p
Sex <0.001 <0.001
Male 44/443 (10%) 1.00 1.00
Female 140/708 (20%) 2.22 1.53–3.21 2.04 1.36–3.07
Age (years) <0.001 0.008
27–49 21/237 (9%) 1.00 1.00
50–59 40/319 (13%) 1.44 0.82–2.53 1.38 0.78–2.47
60–69 78/373 (21%) 2.57 1.52–4.33 2.32 1.35–4.00
70–86 45/222 (20%) 2.24 1.27–3.96 1.97 1.08–3.61
Race † 0.080 0.079
Asian 121/839 (14%) 1.00 1.00
Non-Asian 63/312 (20%) 1.45 0.96–2.20 1.49 0.96–2.32
Weight (kg) <0.001 0.003
≥50 138/977 (14%) 1.00 1.00
45–49 22/102 (22%) 1.60 0.94–2.71 1.51 0.85–2.65
40–44 16/56 (29%) 2.11 1.12–3.99 1.98 1.00–3.93
<40 8/13 (62%) 8.81 2.72–28.5 7.93 2.32–27.1
BMI (kg/m2) 0.002
≥18.5 157/1063 (15%) 1.00
17.0–18.4 13/58 (22%) 1.50 0.77–2.93
16.0–16.9 7/14 (50%) 5.11 1.68–15.5
<16.0 4/6 (67%) 10.2 1.66–62.5
BSA (m2) <0.001
≥1.50 121/898 (13%) 1.00
1.40–1.49 32/155 (21%) 1.65 1.05–2.60
1.30–1.39 18/70 (26%) 2.13 1.17–3.86
<1.30 9/17 (53%) 5.46 1.95–15.3
eGFR (mL/min/1.73 m2) 0.066 0.248
≥90 74/591 (13%) 1.00 1.00
60–89 92/478 (19%) 1.54 1.09–2.19 1.46 1.00–2.12
45–59 14/64 (22%) 1.60 0.82–3.12 1.27 0.63–2.57
<45 4/13 (31%) 2.17 0.63–7.46 1.72 0.48–6.16
ECOG PS 0.460 0.306
0 71/385 (18%) 1.00 1.00
1–2 113/766 (15%) 0.88 0.62–1.24 0.82 0.57–1.19
Hemoglobin (g/L) 0.061 0.600
75–117 56/294 (19%) 1.00 1.00
118–128 55/288 (19%) 1.07 0.70–1.64 1.03 0.66–1.61
129–138 38/281 (14%) 0.69 0.43–1.09 0.76 0.47–1.23
139–185 34/283 (12%) 0.63 0.39–1.02 0.91 0.54–1.53
BMI: body mass index; BSA: body surface area; CI: confidence interval; ECOG PS: Eastern Cooperative Oncology
Group performance status; eGFR: estimated glomerular filtration rate; N: number of patients; OR: odds ratio; * All
logistic regression models were adjusted for any between-study differences in diarrhea incidence. † Limited to
subset of studies (LUX-Lung 1, 2, and 3) that have within-study race differences.
The risk of severe diarrhea associated with each count of risk factors was evaluated separately
for individuals commenced on 40 mg and 50 mg afatinib. The risk of severe diarrhea for individuals
commenced on 40 mg afatinib ranged from 6% for individuals with no risk factors to 33% for
individuals with all three risk factors (Table 3). For individuals commenced on 50 mg afatinib,
the risk ranged from 8% to 43% (Table 3). The C-statistic (discrimination) was 0.65 for individuals
commenced on 40 mg of afatinib and 0.66 for individuals commenced on 50 mg afatinib.
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40 mg Afatinib 50 mg Afatinib
0 5/90 (6%) 9/119 (8%)
1 17/238 (7%) 51/312 (16%)
2 23/152 (15%) 64/198 (32%)
3 6/18 (33%) 9/21 (43%)
1 Female sex, age ≥60 years, and body weight <45 kg.
As a sensitivity analysis, a multivariable logistic regression prediction model was developed
using the same three risk factors, but with age and weight modelled as continuous variables (Table S3).
This model demonstrated similar discrimination performance (C-statistic of 0.65) and good calibration
(Figure S1).
3. Discussion
This study, the largest to evaluate pre-treatment predictors of severe diarrhea with afatinib
treatment for NSCLC, confirmed findings from smaller studies that female sex and very low body
weight are independent risk factors, and further identified older age as an independent risk factor.
A pragmatic method was developed that enabled the prediction of the risk of severe diarrhea based on
the simple count of three risk factors.
It has been previously reported that individuals with female sex, low body weight, or reduced
renal function have moderately higher afatinib plasma concentrations [9]. These prior analyses suggest
that the higher risk associated with low body weight and female sex are likely mediated by increased
exposure to afatinib. Notably, almost all individuals with low body weight (particularly those <45 kg)
were female. eGFR did not demonstrate an independent association with risk of severe diarrhea
once adjusted for weight, age and sex. Age was not previously identified as having a significant
association with afatinib exposure [9], and was not significantly associated with risk of diarrhea in
prior studies [5,6]. However, a univariate association between older age and dose reductions [10] and
toxicity in general [11] has been reported.
This risk score can be used to identify individuals with relatively low risk and relative high risk
of severe diarrhea with use of afatinib. For individuals with low risk, the risk score may help identify
individuals for whom afatinib should be considered as a treatment option. For individuals identified
as being at higher risk, the risk tool may enable planning for closer monitoring during the first
weeks of therapy, consideration of a lower afatinib starting dose, or selection of an alternative EGFR
inhibitor with lower risk of diarrhea. Although there appears to be a relationship between afatinib
concentration and afatinib toxicity, there is currently only preliminary direct evidence to confirm that
starting on an afatinib dose less than 40 mg will reduce the risk of toxicity [12]. Furthermore, the
efficacy impact of commencing on a lower starting dose of afatinib is currently uncertain [12]. There
are now multiple EGFR inhibitor options, including osimertinib [13], a third generation EGFR inhibitor.
Further head-to-head studies are required to understand the optimal sequencing of EGFR inhibitors
and the role of afatinib [14].
A potential limitation of this study is the representativeness of the clinical trial population. While
the trials included use of afatinib across multiple lines of therapy, clinical trials may not represent the
full range of individuals encountered in practice, e.g., patients with an ECOG (Eastern Cooperative
Oncology Group) performance status of two or greater. It will be valuable to evaluate the performance
of the count of these three risk factors in a large contemporary real-world cohort to ensure predictions
are well calibrated. The performance of this risk score was not evaluated in an independent cohort.
Although the risk of overfitting is relatively low due to the large sample size and the restricted set of
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candidate predictors evaluated, the validation of prediction performance in an independent cohort,
preferably a large contemporary real-world cohort, is an important future direction.
Additionally, the analysis included studies with an afatinib starting dose of 50 mg, in addition
to the contemporary use of 40 mg. The starting dose of afatinib was not formally included in the
modelling of risk factors as there was minimal with-in study differences in the afatinib starting
dose (only LUX-Lung 2 [15] included a mix of 40 mg and 50 mg commencing doses). Notably, no
significant differences in the effect size of risk factors were evident between the two starting doses,
thus supporting the use of all available data to identify the major risk factors. Final results of the
model performance were presented separately for 40 mg and 50 mg commencing doses and similar
discrimination performance was apparent between the different commencing doses. For individuals
commenced on 40 mg afatinib, the risk of severe diarrhea was lower overall and was substantively
increased only when at least two of the three risk factors were present.
Finally, age and weight were dichotomized in order to simplify prediction of risk. However, this
likely resulted in some loss of information, particularly for age, which has a relatively linear association
with risk. A cut point of 60 years was selected as it was the median age in the dataset, and on the basis
of the multivariable analysis, risk was identified to be more prominent above this age. Although scored
equivalently, an individual with an age of 40 years was likely to have a lower risk than an individual
aged 55. With respect to weight, individuals of 45 to 50 kg were likely to have a modest increase in
risk that was not accounted for. Nevertheless, the count of risk factors demonstrated comparable
discrimination to the model including age and weight as continuous variables. This suggests that
the simplifications were a reasonable trade-off, particularly if the limitations above are considered in
clinical use.
4. Materials and Methods
4.1. Study Design and Patients
The study was a pooled secondary analysis of patients with advanced NSCLC across seven
clinical trials sponsored by Boehringer Ingelheim: NCT00656136 (LUX-Lung 1) [16], NCT00525148
(LUX-Lung 2) [15], NCT00949650 (LUX-Lung 3) [17], NCT00711594 (LUX-Lung 4) [18], NCT01121393
(LUX-Lung 6) [19], NCT00796549 (BI-1200.40) [20], and NCT00730925 (BI-1200.41) [21]. Anonymized
patient level data were accessed via clinicalstudydatarequest.com. Secondary analysis of anonymized
participant-level trial data was approved by the Southern Adelaide Clinical Human Research Ethics
Committee (SAC HREC EC00188, 4 December 2015). All patients treated with afatinib monotherapy
were included in the analysis.
4.2. Predictor and Outcome Data
Severe diarrhea was defined as either grade 3 or 4 according to the National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.0. Patients were considered at risk of
diarrhea while on afatinib therapy and up to 28 days after cessation.
Pre-treatment predictor variables were selected on the basis of clinical or biological plausibility
and prior evidence of association [5–9]. Predictors evaluated included age, sex, race, body weight, BSA,
BMI, estimated glomerular filtration rate (eGFR) [22], ECOG (Eastern Cooperative Oncology Group)
performance status, and hemoglobin level. Afatinib starting dose was excluded from the analysis on
the basis of insufficient within-study differences [15].
4.3. Statistical Analysis
The association between potential predictors and a serious diarrhea was evaluated using logistic
regression adjusted for any between-study differences in diarrhea incidence. Association was reported
as an odds ratio (OR) with a 95% confidence interval (CI). Due to minimal missing data, a complete
case analysis was undertaken. Potential non-linear association of continuous variables was graphically
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displayed using loess smoothed curves [23]. To aid interpretability, continuous variables were
categorized into four groups based on inspection of the loess curves, using standard cut-points
where possible. Univariate analysis was initially undertaken to evaluate the crude association with
each predictor. Between-study heterogeneity in the predictor effect was evaluated using statistical
interaction with the study variable.
Multivariable logistic regression analysis included all variables from the univariate analysis, with
the exception that due to the strong correlation between weight, BSA, and BMI, only one variable
was included based on the univariate analysis. The results of the multivariable analysis were used to
identify the major independent risk factors and reasonable cut points for any continuous risk factors.
For simplicity, a single cut point was sought for each major risk factor identified, with the cut point
preferably selected such that the major risk factors identified had similar effect size. The risk score was
defined as the count of the major independent risk factors present.
To evaluate the performance of the risk score, individuals commenced on 40 mg afatinib were
evaluated separately from individuals commenced on 50 mg afatinib. The observed risk of severe
diarrhea associated with each risk score was estimated by the number of patient who experienced
severe diarrhea divided by the total number patients. Discrimination performance of the risk score
and the prediction model was evaluated using the area under the receiver operating characteristic
curve (C-statistic) [24].
As a sensitivity analysis, a logistic regression model was developed using the multivariable
fractional polynomial approach [25] and including the same major risk factors included in the risk
score, but without categorization of continuous variables. Goodness-of-fit was visually assessed by
plotting a loess calibration curve of predicted probabilities with observed risk [26]. All analyses were
two-sided and undertaken using the R statistical environment version 3.3.0.
5. Conclusions
Low body weight, female sex, and older age are independent significant risk factors for severe
diarrhea with use of afatinib for NSCLC. A simple count of risk factors can provide an estimate of an
individual’s risk.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/10/384/
s1. Table S1: Summary by study of pre-treatment participant characteristics. Table S2: Multivariable logistic
regression analysis of association between pre-treatment characteristics and grade ≥3 diarrhea with afatinib,
including adjustment for afatinib starting dose. Table S3: Coefficients of multivariable logistic regression model of
severe diarrhea with afatinib. Figure S1: Calibration plot for the multivariable logistic regression model of severe
diarrhea with afatinib.
Author Contributions: Conceptualization, A.M.H., A.R., and M.J.S.; Formal analysis, A.M.N. and M.J.S.; Funding
acquisition, A.M.H., A.R., and M.J.S.; Methodology, A.M.H., M.N., C.S.K., A.R., and M.J.S.; Writing—Original
draft, A.M.N. and M.J.S.; Writing—Review and editing, A.M.H., C.S.K., A.R., and M.J.S.
Funding: This work was funded by the National Health and Medical Research Council, grant number 1100179;
and the National Breast Cancer Foundation, grant number PF-17-007.
Acknowledgments: The authors acknowledge the assistance of Sasha Zhang for assistance with data management
and preparation.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Greenhalgh, J.; Dwan, K.; Boland, A.; Bates, V.; Vecchio, F.; Dundar, Y.; Jain, P.; Green, J.A. First-line treatment
of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung
cancer. Cochrane Database Syst. Rev. 2016. [CrossRef] [PubMed]
Cancers 2018, 10, 384 9 of 10
2. Park, K.; Tan, E.H.; O’Byrne, K.; Zhang, L.; Boyer, M.; Mok, T.; Hirsh, V.; Yang, J.C.H.; Lee, K.H.; Lu, S.; et al.
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung
cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016, 17, 577–589.
[CrossRef]
3. Takeda, M.; Okamoto, I.; Nakagawa, K. Pooled safety analysis of EGFR-TKI treatment for EGFR
mutation-positive non-small cell lung cancer. Lung Cancer 2015, 88, 74–79. [CrossRef] [PubMed]
4. Barron, F.; De la Torre-Vallejo, M.; Luna-Palencia, R.L.; Cardona, A.F.; Arrieta, O. The safety of afatinib for
the treatment of non-small cell lung cancer. Expert Opin. Drug Saf. 2016, 15, 1563–1572. [CrossRef] [PubMed]
5. Wada, Y.; Koyama, S.; Kuraishi, H.; Miyahara, T.; Yoshiike, F.; Agatsuma, T.; Yamamoto, R.; Ono, Y.; Suzuki, T.;
Hachiya, T.; et al. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer:
A Nagano Lung Cancer Research Group observational study. Respir. Investig. 2016, 54, 462–467. [CrossRef]
[PubMed]
6. Arrieta, O.; De la Torre-Vallejo, M.; Lopez-Macias, D.; Orta, D.; Turcott, J.; Macedo-Perez, E.O.;
Sanchez-Lara, K.; Ramirez-Tirado, L.A.; Baracos, V.E. Nutritional Status, Body Surface, and Low Lean
Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced
by Afatinib in Patients With Non-Small Cell Lung Cancer. Oncologist 2015, 20, 967–974. [CrossRef] [PubMed]
7. Ueda, Y.; Suzuki, H.; Kondo, Y.; Okamoto, N.; Kumode, A.; Usui, N.; Nakano, H.; Kimura, T.; Sando, M.;
Shimura, K.; et al. Risk Factors of Afatinib Induced Diarrhea: A Retrospective Study. Iryo Yakugaku (Jpn. J.
Pharm. Health Care Sci.) 2016, 42, 670–677. [CrossRef]
8. Giotrif: European Public Assessment Report—Product Information. 2013. Available online:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002280/
human_med_001698.jsp (accessed on 20 April 2018).
9. Freiwald, M.; Schmid, U.; Fleury, A.; Wind, S.; Stopfer, P.; Staab, A. Population pharmacokinetics of afatinib,
an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother. Pharmacol. 2014,
73, 759–770. [CrossRef] [PubMed]
10. Yang, J.C.; Sequist, L.V.; Zhou, C.; Schuler, M.; Geater, S.L.; Mok, T.; Hu, C.P.; Yamamoto, N.; Feng, J.;
O‘Byrne, K.; et al. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive
lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann. Oncol. 2016, 27,
2103–2110. [CrossRef] [PubMed]
11. Wu, Y.-L.; Sequist, L.V.; Tan, E.-H.; Geater, S.L.; Orlov, S.; Zhang, L.; Lee, K.H.; Tsai, C.-M.; Kato, T.;
Barrios, C.H.; et al. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive
Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7
Trials. Clin. Lung Cancer 2018, 19, e465–e479. [CrossRef] [PubMed]
12. Yang, C.-J.; Tsai, M.-J.; Hung, J.-Y.; Lee, M.-H.; Tsai, Y.-M.; Tsai, Y.-C.; Hsu, J.-F.; Liu, T.-C.; Huang, M.-S.;
Chong, I.-W. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib
40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
BMC Pharmacol. Toxicol. 2017, 18, 82. [CrossRef] [PubMed]
13. Soria, J.-C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.;
Imamura, F.; Nogami, N.; Kurata, T.; et al. Osimertinib in Untreated EGFR-Mutated Advanced
Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 113–125. [CrossRef] [PubMed]
14. Hirsh, V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: Optimal
sequential therapy with EGFR tyrosine kinase inhibitors. Ther. Adv. Med. Oncol. 2018, 10. [CrossRef]
[PubMed]
15. Yang, J.C.; Shih, J.Y.; Su, W.C.; Hsia, T.C.; Tsai, C.M.; Ou, S.H.; Yu, C.J.; Chang, G.C.; Ho, C.L.; Sequist, L.V.;
et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations
(LUX-Lung 2): A phase 2 trial. Lancet Oncol. 2012, 13, 539–548. [CrossRef]
16. Miller, V.A.; Hirsh, V.; Cadranel, J.; Chen, Y.M.; Park, K.; Kim, S.W.; Zhou, C.; Su, W.C.; Wang, M.; Sun, Y.; et al.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of
erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised
trial. Lancet Oncol. 2012, 13, 528–538. [CrossRef]
17. Sequist, L.V.; Yang, J.C.; Yamamoto, N.; O’Byrne, K.; Hirsh, V.; Mok, T.; Geater, S.L.; Orlov, S.; Tsai, C.M.;
Boyer, M.; et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung
adenocarcinoma with EGFR mutations. J. Clin. Oncol. 2013, 31, 3327–3334. [CrossRef] [PubMed]
Cancers 2018, 10, 384 10 of 10
18. Katakami, N.; Atagi, S.; Goto, K.; Hida, T.; Horai, T.; Inoue, A.; Ichinose, Y.; Koboyashi, K.; Takeda, K.;
Kiura, K.; et al. LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer
who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 2013, 31, 3335–3341.
[CrossRef] [PubMed]
19. Wu, Y.L.; Zhou, C.; Hu, C.P.; Feng, J.; Lu, S.; Huang, Y.; Li, W.; Hou, M.; Shi, J.H.; Lee, K.Y.; et al. Afatinib
versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung
cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol.
2014, 15, 213–222. [CrossRef]
20. Cappuzzo, F.; Finocchiaro, G.; Grossi, F.; Bidoli, P.; Favaretto, A.; Marchetti, A.; Valente, M.L.; Cseh, A.;
Clementi, L.; Massey, D.; et al. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR
FISH-positive non-small-cell lung cancer. J. Thorac. Oncol. 2015, 10, 665–672. [CrossRef] [PubMed]
21. De Greve, J.; Moran, T.; Graas, M.P.; Galdermans, D.; Vuylsteke, P.; Canon, J.L.; Schallier, D.; Decoster, L.;
Teugels, E.; Massey, D.; et al. Phase II study of afatinib, an irreversible ErbB family blocker, in
demographically and genotypically defined lung adenocarcinoma. Lung Cancer 2015, 88, 63–69. [CrossRef]
[PubMed]
22. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; Greene, T.; Rogers, N.; Roth, D. A more accurate method to estimate
glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal
Disease Study Group. Ann. Intern. Med. 1999, 130, 461–470. [CrossRef] [PubMed]
23. Cleveland, W.S.; Devlin, S.J. Locally Weighted Regression: An Approach to Regression Analysis by Local
Fitting. J. Am. Stat. Assoc. 1988, 83, 596–610. [CrossRef]
24. Steyerberg, E.W.; Vergouwe, Y. Towards better clinical prediction models: Seven steps for development and
an ABCD for validation. Eur. Heart J. 2014, 35, 1925–1931. [CrossRef] [PubMed]
25. Sauerbrei, W.; Meier-Hirmer, C.; Benner, A.; Royston, P. Multivariable regression model building by using
fractional polynomials: Description of SAS, STATA and R programs. Comput. Stat. Data Anal. 2006, 50,
3464–3485. [CrossRef]
26. Van Calster, B.; Nieboer, D.; Vergouwe, Y.; De Cock, B.; Pencina, M.J.; Steyerberg, E.W. A calibration hierarchy
for risk models was defined: From utopia to empirical data. J. Clin. Epidemiol. 2016, 74, 167–176. [CrossRef]
[PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
